Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
|Articles|August 28, 2013
2013 Entrepreneur of the Year Award
This award honors a pharmacist who owns a pharmacy in whole or part and demonstrates entrepreneurial spirit in growing its business.
Advertisement
This video features the winner and honorees for the 2013 Next-GenerationTM Entrepreneur of the Year award, presented by Pharmacy Times and Parata Systems:
- Winner: Bob Lomenick, RPh, Tyson Drug Company, Holly Springs, MS
- Honoree: Joe Craft, RPh, Plain City Druggist, Plain City, OH
- Honoree: Christian Tadrus, PharmD, RPh, Sam’s Health Mart Pharmacies, Moberly, MO
Advertisement
Related to this article
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Flu Vaccination Linked to Fewer Severe Outcomes in Older Adults, Fewer ED Visits in Children
2
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5